An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
Read more: Stem Cell Injection May Soon Reverse Vision Loss Caused By Age-Related Macular Degeneration
The Latest on: Age-Related Macular Degeneration
[google_news title=”” keyword=”Age-Related Macular Degeneration” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Age-Related Macular Degeneration
- Macular degeneration topic of Viroqua library programon April 18, 2024 at 12:30 pm
McIntosh Memorial Library, in partnership with the Vernon County Over 50 Club, are hosting a presentation with Dr. Troy McKay an optometrist with Gundersen Health System.
- Rheumatoid arthritis causally linked to increased risk of age-related macular degeneration, suggests studyon April 18, 2024 at 8:30 am
Rheumatoid arthritis causally linked to increased risk of age-related macular degeneration, suggests a study published in the Medicine (Baltimore).This study's goal is to evaluate if there is ...
- Neovascular Age-Related Macular Degenerationon April 17, 2024 at 5:00 pm
Choroidal neovascularization is the primary cause of visual loss in patients with age-related macular degeneration. Current treatments, proven to offer a benefit for these patients through ...
- InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degenerationon April 16, 2024 at 5:00 am
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical ...
- Alternative Anti-VEGF Treatment Regimens in Exudative Age-related Macular Degenerationon April 15, 2024 at 5:00 pm
Six clinical studies (A Study of rhuFAB V2 [Ranibizumab] in Subjects with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [PIER], Prospective Optical Coherence ...
- Moran Eye Center Researchers Lead Field with New Age-Related Macular Degeneration Discoveryon April 15, 2024 at 5:00 pm
Age-related macular degeneration (AMD) affects close to 200 million people worldwide and causes between 15 and 20 percent of irreversible vision loss for people over 50 in Europe and North America.
- Wet vs. Dry Macular Degeneration: What Is the Difference?on April 14, 2024 at 5:00 pm
Both types of age-related macular degeneration (AMD) can cause blurriness and visual changes. Dry AMD progresses slowly and causes permanent damage, while wet AMD is more severe but more treatable.
- Age-Related Macular Degeneration and Diabetic Nephropathy: Is there a Connection?on April 9, 2024 at 5:00 pm
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Diabetic nephropathy and age-related macular degeneration (AMD) both lead to serious complications; diabetic ...
- Atrophic macular degeneration: What to knowon March 25, 2024 at 5:00 pm
Atrophic macular degeneration, or geographic atrophy, is an advanced stage of dry age-related macular degeneration. Destruction of the cells — known as atrophy — in the retina can eventually ...
- How Macular Degeneration Changes What You Seeon March 21, 2024 at 5:00 pm
Age-related macular degeneration (AMD) is a condition that causes loss of central vision but doesn't affect peripheral (side) vision. Dry AMD and the even more serious wet AMD both cause vision ...
via Bing News